New ETF Book by Larry Connors - Click here to read more
-- August 18, 2009 DivX, Inc. (Nasdaq: DIVX | Quote | Chart | News | PowerRating) trading at $5.14 on a volume of 21,297 shares.
In a press release out on August 18, 2009 DivX and NEC Electronics Announce Multi-Year Licensing Agreement for DivX Plus(TM) HD Certification
NEC Electronics' EMMA(TM) chips to power advanced Blu-ray players, digital TVs and set-top boxes
SAN DIEGO and KAWASAKI, Japan, Aug 18, 2009 -- DivX, Inc. (Nasdaq: DIVX), a digital media company, and NEC Electronics Corporation (TSE: 6723), a leading provider of semiconductor solutions, today announced a multi-year licensing agreement covering the integration of DivX Plus(TM) HD technology into NEC Electronics' 'Enhanced Multi-Media Architecture' (EMMA(TM)). NEC Electronics' EMMA chips are designed to power next-generation Blu-ray players, digital televisions (DTVs) and set-top boxes, to enable consumer electronics manufacturers to deliver a high-quality and comprehensive high definition digital media experience to consumers.
About DivX
DivX, Inc. is a digital media company that enables consumers to enjoy a high-quality video experience across any kind of device. DivX creates, distributes and licenses digital video technologies that span the "three screens" comprising today's consumer media environment--the PC, the television and mobile devices. Over 200 million DivX devices have shipped into the market from leading consumer electronics manufacturers. DivX also offers content providers and publishers a complete solution for the distribution of secure, high-quality digital video content. Driven by a globally recognized brand and a passionate community of hundreds of millions of consumers, DivX is simplifying the video experience to enable the digital home.
-- August 18, 2009 DURECT Corporation (Nasdaq: DRRX | Quote | Chart | News | PowerRating) trading at $2.37 on a volume of 30,715 shares
In a press release on August 18, 2009 DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
CUPERTINO, Calif., Aug 18, 2009 -- DURECT Corporation (Nasdaq: DRRX | Quote | Chart | News | PowerRating) today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR(R) Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder (ADHD). This drug candidate (ORADUR-ADHD) is intended to provide once-a-day dosing with added tamper-resistant characteristics to address common methods of abuse and misuse of these types of drugs. North American, European, Japanese and select other countries' rights to this drug candidate are retained by DURECT.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
-- August 18, 2009 MicroStrategy(R) Incorporated (Nasdaq: MSTR | Quote | Chart | News | PowerRating) trading at $61.97 on a volume of 20,831 shares.
In a press release out on August 18, 2009 MicroStrategy Augments OEM Program with New Product Capabilities for SaaS Companies
MCLEAN, Va., Aug 18, 2009 -- MicroStrategy(R) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that it has enhanced its OEM program with new product capabilities for Software-as-a-Service (SaaS) companies.
About MicroStrategy
Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (Nasdaq: MSTR | Quote | Chart | News | PowerRating) is available at www.microstrategy.com.
-- August 18, 2009 SanDisk Corporation (NASDAQ: SNDK | Quote | Chart | News | PowerRating) trading at $16.68 on a volume of 1.40M shares.
In a press release out on August 18, 2009 SanDisk Enhances Cruzer Enterprise Secure USB Drives to Meet the Needs of Federal Government Employees
Milpitas, CA, Aug 18, 2009 -- SanDisk Corporation (NASDAQ: SNDK), the global leader in flash memory cards, today announced that its SanDisk(R) Cruzer(R) Enterprise secure USB flash drives (http://www.sandisk.com/business-solutions/enterprise/products.aspx) are now enhanced to meet the unique requirements of government employees. The Cruzer Enterprise design was independently tested and certified under Military Standard 810-F environmental standards in addition to being suitable for use by the visually-impaired under Section 508 requirements. Cruzer Enterprise drives feature industry-leading cryptographic modules and encryption algorithms, durable waterproof design, and are fully compliant with Trade Agreements Act (TAA) requirements for purposes of U.S. Government procurements. In addition, the Cruzer Enterprise line of flash drives is listed for Common Criteria certification (http://www.dsd.gov.au/infosec/evaluation_services/epl/In_Evaluation/SanDiskCruzerEnterpriseFIPS.html), which it is expected to receive next month.
About SanDisk:
SanDisk Corporation is the global leader in flash memory cards, from research, manufacturing and product design to consumer branding and retail distribution. SanDisk's product portfolio includes flash memory cards for mobile phones, digital cameras and camcorders; digital audio/video players; USB flash drives for consumers and the enterprise; embedded memory for mobile devices; and solid state drives for computers. SanDisk (www.sandisk.com/corporate]) is a Silicon Valley-based S&P 500 company with more than half its sales outside of the United States.
-- August 18, 2009 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT | Quote | Chart | News | PowerRating) trading at $8.95 on a volume of 6,295 shares.
In a press release out on August 18, 2009 Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement
RICHMOND, Calif., Aug 18, 2009 -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT | Quote | Chart | News | PowerRating) today announced plans to reduce operating expenses by eliminating certain staff positions following its recently announced License and Collaboration Agreement with Purdue Pharmaceutical Products to commercialize Intermezzo((R) )(zolpidem tartrate sublingual tablet) in the United States.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: www.transcept.com.
-- August 18, 2009 Geron Corporation (Nasdaq:GERN) trading at $6.46 on a volume of 3.36M shares
In a press release out on August 18, 2009 Geron's IND for Spinal Cord Injury Placed on Hold
MENLO PARK, Calif., Aug 18, 2009 -- Geron Corporation (Nasdaq:GERN) today announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency's review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. For more information, visitwww.geron.com.
About PicksThatMove.com
www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com
www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: PicksThatMove.com e-mail: Info@picksthatmove.com WWW: http://www.picksthatmove.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
